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ABSTRACT
DNA methylation is an epigenetic modification
involved in both normal developmental processes
and disease states through the modulation of gene
expression and the maintenance of genomic orga-
nization. Conventional methods of DNA methylation
analysis, such as bisulfite sequencing, methylation
sensitive restriction enzyme digestion and array-
based detection techniques, have major limita-
tions that impede high-throughput genome-wide
analysis. We describe a novel technique, MBD-
isolated Genome Sequencing (MiGS), which
combines precipitation of methylated DNA by
recombinant methyl-CpG binding domain of MBD2
protein and sequencing of the isolated DNA by a
massively parallel sequencer. We utilized MiGS to
study three isogenic cancer cell lines with varying
degrees of DNA methylation. We successfully
detected previously known methylated regions in
these cells and identified hundreds of novel
methylated regions. This technique is highly
specific and sensitive and can be applied to any bio-
logical settings to identify differentially methylated
regions at the genomic scale.
INTRODUCTION
DNA cytosine methylation is the covalent addition of a
methyl group to the 5 position of cytosine. In humans,
DNA methylation occurs predominantly in a CpG
dinucleotide context and is catalyzed by DNA
methyltransferases (1–3). Dense clusters of CpG
dinucleotides, termed CpG islands, are present in
roughly 40% of gene promoters, and methylation of
these regions is associated with transcriptional silencing
(4,5). DNA methylation is essential for normal
developmental processes, such as imprinting (6) and
X chromosome inactivation (7). Dysregulation of DNA
methylation occurs in disease states such as cancer,
where promoter CpG island hypermethylation leads to
inactivation of tumor suppressor genes (8,9). Thus,
many tumor suppressors classically identiﬁed through
mutation analyses, such as APC (10,11), BRCA1 (12,13),
and CDKN2A (14,15), have also been found to be
transcriptionally silenced by promoter hypermethylation.
Since epigenetic abnormalities are recognized to be
integral to the pathogenesis of cancer, the Cancer
Genome Atlas Project has aims to map DNA methylation
in several common cancers. However, current methods all
have major shortcomings that prevent a truly high-
throughput, unbiased, and exhaustive proﬁling of
genomic cytosine methylation.
Bisulﬁte sequencing, the gold standard for cytosine
methylation analysis, provides single base pair resolution
of methylation patterns but requires sequencing of the
entire genome (16). The characterization of DNA
methylation of a single genome by bisulﬁte sequencing
currently requires around 150 lanes of Illumina Genome
Analyzer II (GAII) in order to obtain suﬃcient coverage
to accurately and quantitatively determine the
methylation state of most cytosines. For this reason, it is
impractical to apply this method to the study of multiple
biological samples. Alternative approaches are based on
speciﬁc enrichment of methylated portions of the genome.
Methylation sensitive restriction enzyme digestion
allows the enrichment of highly methylated regions of
the genome (17). However, it introduces recognition
site biases, has a relatively poor resolution, and is
prone to false positives due to incomplete digestion.
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captures any DNA fragment containing one or more
methylated cytosines (18). As a result, sporadically
methylated sequences can comprise a signiﬁcant por-
tion of the data generated by this method. Finally,
detection of methylated regions following either one of
these methods is often conducted by hybridizing
the DNA to a tilling array (17–20). Array design
introduces an ascertainment bias, constraining novelty of
the results. Additionally, probe sequences heavily inﬂu-
ence detection speciﬁcity and sensitivity. This is particu-
larly problematic in the context of studying DNA
methylation because many methylated regions have high
GC content.
To overcome these limitations, we have combined
methyl CpG binding domain (MBD) precipitation of
genomic DNA with massively parallel sequencing.
Neither procedure introduces sequence bias, and the
combination allows for high-throughput analysis of
multiple samples. In this MBD-isolated Genome
Sequencing (MiGS) method, we used recombinant
MBD of MBD2 protein to precipitate densely meth-
ylated sequences obtained after random shearing of
genomic DNA. In vivo, MBD2 binds speciﬁcally to
methylated CpGs via its MBD and facilitates gene
silencing through its innate transcriptional repression
domain and recruitment of additional transcription
inhibitors (21). Importantly, MBD binds with
increasing aﬃnity to multiple methylated cytosines in
close proximity and will, therefore, predominantly
precipitate biologically relevant, multiply methylated
fragments as opposed to sporadically methylated CpGs
of uncertain biological relevance (22). Random shearing
of the genome by sonication minimizes sequence-
speciﬁc fragmentation, as compared to restriction
enzyme digestion. Finally, the massively parallel
sequencing provides a high throughput detection method
without any ascertainment bias.
We used MiGS to characterize genome-wide
DNA methylation proﬁles of three isogenic human
cancer cell lines harboring diﬀerent levels of DNA
methylation. The parental HCT116 colon cancer
cells have average levels of DNA methylation found in
many colon cancer cells. The DICER
ex5 cells are derived
from HCT116 through truncation of DICER1 alleles and
show localized changes of DNA methylation at a small
number of gene promoters (23). Finally, the DNMT1,
DNMT3b double knockout (DKO) cells derived from
HCT116 retain <5% of overall DNA methylation, as
compared to HCT116 parental cells, and exhibited loss
of promoter methylation at most loci analyzed so far
(24). Our MiGS data describe the DNA methylation
patterns in the entire genomes of these cell lines. We
show that MiGS eﬃciently detected previously known
DNA methylation and identiﬁed numerous novel DNA
methylation sites. Our results strongly support that
MiGS is a speciﬁc, sensitive, and high-throughput tech-
nique for the study of genome-wide DNA methylation
patterns.
MATERIALS AND METHODS
Cell culture
HCT116 colon cancer cells were cultured in McCoy’s 5A
media supplemented with 10% fetal bovine serum. DKO
(24) and DICER
ex5 cells (25) are isogenic derivatives of
HCT116 and were cultured in the same manner. Cells were
harvested by scraping, and cell pellets were rinsed twice
with 1X PBS.
DNA sample preparation
Genomic DNA was extracted from cell pellets by incuba-
tion in cell lysis buﬀer [20mM Tris (pH 8), 20mM EDTA,
2% SDS and 0.5mg/ml Proteinase K] overnight at 55 C
followed by phenol:chloroform extraction and ethanol
precipitation. Genomic DNA was fragmented to  150–
600bp by sonication in 1X BW buﬀer [4% glycerol,
1mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 50mM
NaCl, 10mM Tris–HCl (pH 7.4), 0.2% Tween-20 and
1X Complete EDTA-free Protease Inhibitor cocktail],
and fragment sizes were veriﬁed by gel electrophoresis in
1% agarose gels. The fragmented samples were puriﬁed
through QIAquick PCR cleanup columns (Qiagen) fol-
lowing manufacturer’s protocol to exclude fragments
smaller than 100bp. Five micrograms of puriﬁed DNA
fragments per sample was used in each immunopre-
cipitation reaction.
Isolation of methylated DNA by recombinant MBD
His-tagged recombinant MBD of MBD2 (MBD2_MBD)
protein was expressed and puriﬁed as previously described
(22,26). Recombinant MBD2_MBD was conjugated to
magnetic beads (Dynal) by incubation overnight with
rotation at 4 C. The conjugation mixture contained
41.7ml/ml protein G magnetic bead slurry (Invitrogen),
10mg/ml anti-his RGS antibody (Qiagen), 1mg/ml self-
ligated pCR4-TOPO vector (Invitrogen), 160 nM
puriﬁed recombinant MBD2_MBD proteins and 1X BW
buﬀer. The MBD-magnetic bead conjugates were washed
with 1 volume of cold 1X BW buﬀer and then re-
suspended in 1 volume fresh 1X BW buﬀer. Five milliliters
of the re-suspended mixture was used to precipitate 5mgo f
sheared DNA fragments by incubation overnight with
rotation at 4 C. The precipitation complex was washed
5  with 1 volume of 1X BW buﬀer. DNA was eluted
by incubation of the precipitation complex in freshly
prepared Elution Buﬀer [20ml Tris (pH 8), 10mM
EDTA, 0.5% SDS and 500mg/ml Proteinase K] at 60 C
for 2h with shaking. The eluted DNA was extracted
with phenol:chloroform, precipitated by isopropanol,
and re-suspended in 45mld H 2O.
Library preparation and sequencing
Ten nanograms of MBD-isolated DNA per sample was
processed with the ChIP-Seq Sample Prep Kit (Illumina)
following manufacturer’s protocol to construct the
sequencing libraries. Sequencing libraries were analyzed
on the BioAnalyzer (Agilent), and a tight distribution of
insert size around 120bp was observed for all libraries.
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long reads.
Mapping of sequence reads
All sequence reads were mapped to the reference human
genome (NCBI Build 36.1, UCSC Hg18) using the Bowtie
algorithm (27). Only reads that mapped unambiguously to
single genomic locations were considered for further
analysis. In addition, when several reads mapped to the
exact same location and in the same orientation, these
reads were deemed to represent ampliﬁed products
generated from a single library insert. Only one of such
reads was considered for further analysis. Since the
average DNA fragment length used to generate reads
was 120bp, the reference human genome was split into
non-overlapping 100-bp windows. Each 36-bp sequence
was extended to 120bp and assigned to the 100-bp
window that was most covered by this extended read.
Sequence reads not mapped to the reference genome
were mapped using Bowtie (27) against the raw Sanger
sequence data for Craig Venter’s genome (28).
Repeat element analysis
Sequence reads were analyzed using RepeatMasker (29) to
ascertain the composition of repeat elements in each
dataset.
Determination of signiﬁcantly methylated loci
To determine the signiﬁcance cut-oﬀ for considering one
locus methylated, we assumed that windows with one or
two reads were mainly background to ﬁt a null model,
which determines the number of windows with a given
number of reads expected solely by chance. By comparing
the observed number of windows with a given number of
reads to the expected number of windows with the same
given number of reads under the null model, a false dis-
covery rate (FDR) was calculated for each window. Using
the average expected number of reads per window (the
total number of reads divided by the total number of
100-bp windows in the genome) as   yielded similar
FDRs. Diﬀerential methylation between HCT116 and
DICER
ex5 was assessed by testing whether the number
of reads observed in each window diﬀer between
samples corrected for the total number of uniquely
mapped reads in each sample using Fisher’s exact test.
Sampling curves
To estimate whether the number of reads generated was
suﬃcient to assess genome-wide DNA methylation
patterns, sampling curves were generated for HCT116
and DICER
ex5. We combined the dataset analyzed in
this article with additional 28256599 and 19669907
reads generated for HCT116 and DICER
ex5 from
the same libraries. 1, 2.5, 5, 7.5, 10, 15, 20, 30 and
35 million reads were randomly sampled without replace-
ment to determine how many methylated windows could
be identiﬁed in each subset. This analysis was performed
separately for all methylated windows ( 4 reads) and for
highly methylated windows ( 10 reads). Ten random
iterations were performed at each chosen number of
reads, and the average numbers are displayed in Figure 2.
Genomic annotations
Each methylated window was categorized according to its
relative position to RefSeq gene annotations (UCSC
Hg18). Windows located within 500bp of transcription
start sites were annotated as 50-end, and windows within
500bp of transcription stop sites were annotated as 30-end.
Windows located between the most upstream transcrip-
tion start site and the most downstream stop site, but
not previously annotated as 50-end or 30-end, were
annotated as genic. All remaining windows were consid-
ered as intergenic. CpG island and miRNA annotations
were retrieved from the UCSC Genome Browser. For
miRNA, 500bp on either side of the annotated coding
sequence were used to include possible regulatory
elements. A summary of the Broad Institute datasets for
GM12878, HUVEC, K562 and NHEK cells was used for
annotating CTCF binding sites.
Gene expression analysis
Diﬀerential gene expression data from HCT116, DAC-
treated HCT116, and DKO cells were obtained from
Gene Expression Omnibus (GSE4763). For each probe
on the Agilent microarray, the mean log2 change in gene
expression was calculated for the DAC-treated HCT116/
HCT116 (chemical demethylation) and DKO/HCT116
(genetic demethylation) pairs. The signiﬁcance of diﬀeren-
tial gene expression for genes with methylation diﬀerences
was assessed using Student’s t-test.
Bisulﬁte sequencing
Genomic DNA was bisulﬁte converted using the EpiTect
kit (Qiagen) following manufacturer’s protocol. The PCR
amplicons were gel-puriﬁed and cloned into pCR4-TOPO
vector (Invitrogen). At least 10 clones were sequenced
individually on an ABI3730xl DNA Analyzer to ascertain
the methylation patterns of each locus. The percentage of
methylation is calculated as number of methylated
cytosines divided by the total number of cytosines in all
the amplicons analyzed. The percentages are rounded to
the nearest integer in Table 2.
RESULTS
MiGS accurately identiﬁes methylated regions
We performed MBD precipitation of methylated genomic
DNA in HCT116, DICER
ex5 and DKO cell lines, and
prepared sequencing libraries for each sample. The
libraries for HCT116, DICER
ex5 and DKO were
sequenced using 2, 2 and 1 lanes, respectively of a GAII.
We generated 19041613 reads from HCT116, 18315610
reads from DICER
ex5 and 4393056 reads from DKO.
Approximately 30% of all reads could be unambiguously
mapped to a unique location in the human genome (NCBI
Build 36.1) using the Bowtie algorithm (27) (Table 1).
Another 10–12% of the reads mapped to multiple
locations in the reference genome. Finally, we postulated
Nucleic AcidsResearch, 2010, Vol.38,No. 2 393that many sequence reads that did not match sequences on
the assembled human genome originate from centromeric
and sub-telomeric regions of the genome that have not
been successfully assembled. These sequences, however,
should be present in the shotgun sequencing data of
Venter’s genome (28). Indeed, 4–22% of sequencing
reads matched to the unassembled Venter’s genome
dataset but not in the assembled reference genome
(Table 1). Finally, we annotated 13–20% of the total
sequences as repeat elements (Supplementary Figure S1).
Sequencing reads that cannot be mapped to the human
genome likely (i) contain too many nucleotide diﬀerences
to the reference sequences due to sequencing errors,
polymorphisms, or insertions/deletions or (ii) originate
from regions overlapping genomic rearrangements (D.S.
and A.H.T., unpublished data).
Reads that were unambiguously mapped to a single
location in the reference human genome were assigned
to non-overlapping 100-bp windows. To determine
which windows contained more reads than would be
expected by chance, we ﬁtted a null distribution to our
data and estimated a FDR for each window. We deter-
mined that 100-bp windows containing four or more reads
were unlikely to be generated by chance (FDR<0.01) and
therefore signiﬁcantly methylated. Overall we identiﬁed
171338, 166568 and 59774 non-overlapping windows
with signiﬁcant evidence of DNA methylation in
HCT116, DICER
ex5, and DKO, respectively and focused
on these regions in subsequent analyses.
For validation, bisulﬁte sequencing was performed on
17 randomly selected regions that were identiﬁed as
methylated by MiGS. These regions represent a wide
Table 2. Experimental validation by bisulﬁte sequencing
Locus analyzed MiGS (No. of methylated windows) Bisulﬁte Seq. (% MetC)
Coordinates Name
a Total HCT116 DICER
ex5 DKO HCT116 DICER
ex5 DKO
Signiﬁcantly methylated in HCT116 and DICER
ex5 in MiGS assay
chr19:1507384-1507703 MEX3D 5 5 5 5 99 99 41
chr5:92949531-92949838 NR2F1 4 4 4 4 100 99 37
chr1:154452833-154453297 PMF1 5 5 5 3 98 98 31
chr1:211190670-211190970 VASH2 4 3 2 0 76 28 16
chrX:21302569-21302868 CNKSR2 4 4 4 1 95 96 13
chr1:247108292-247108567 ZNF672 4 4 4 4 98 98 11
chrX:23262922-23263235 PTCHD1 4 4 4 2 94 96 6
chr1:164401866-164402277 FAM78B 5 5 5 1 93 94 1
chr16:33869047-33869405 Peri-16 5 5 5 0 96 96 1
chr10:83624002-83624444 NRG3 5 5 5 0 94 92 1
chr20:26136535-26136825 mir663 4 3 3 0 99 98 1
chr1:47654991-47655443 FOXE3 6 6 6 0 97 98 1
chr10:79066821-79067106 KCNMA1 4 4 4 0 98 99 1
chr9:23810766-23810968 ELAVL2 3 3 3 0 98 98 1
chr9:25667441-25667703 TUSC1 4 4 4 0 95 92 1
chr10:31649125-31649519 ZEB1 5 5 1 0 72 25 0
chr3:128830800-128831068 PODXL2 3 3 3 0 87 34 NA
b
No evidence of methylation in HCT116 and DICER
ex5 in MiGS assay
chr19:44113033-44113323 S/M
c 40 0 0 1 N A N A
chr8:145209542-145209851 GPAA1 40 0 0 1 N A N A
chr7:105539547-105539910 SYPL1 50 0 0 0 N A N A
chr18:10515854-10516103 NAPG 40 0 0 0 N A N A
chr1:143920369-143920682 NOTCH2NL 40 0 0 0 N A N A
aName of the closest RefSeq gene.
bBisulﬁte sequencing not performed.
cSARS2/MRPS12 bidirectional promoter.
Table 1. Mapping distribution of DNA sequence reads
HCT116 DICER
ex5 DKO
No. of reads 19041613 18315610 4393056
Reads mapped uniquely to Human Genome 7102330 (37%) 6920 203 (38%) 1207400 (27%)
Non-repeat 5767100 5620190 977692
Repeat elements 1335230 1300013 229708
Reads mapped to multiple locations on the Human Genome 1978515 (10%) 2138088 (12%) 439995 (10%)
Non-repeat 811412 793801 103734
Repeat elements 1167103 1344287 336261
Reads mapped to the unassembled Human Genome 4210471 (22%) 3811890 (21%) 167253 (4%)
Non-repeat 3368209 3083404 159548
Repeat elements 842262 728486 7705
Others not mapped 5694794 (30%) 5445429 (30%) 2578408 (59%)
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CpG islands, gene promoters, intragenic and intergenic
sequences (Table 2 and Supplementary Table S1). All 17
tested regions were validated by bisulﬁte sequencing
(Table 2). For example, MiGS determined that the peri-
centromeric CpG island of chromosome 16 was
methylated in HCT116 and DICER
ex5 cells but not in
DKO cells (Supplementary Figure S2). Bisulﬁte
sequencing conﬁrmed these patterns (Figure 1A).
Conversely, the promoter CpG island of PTCHD1 was
determined to have high levels of methylation in both
HCT116 and DICER
ex5 cells and low, but signiﬁcant,
levels of methylation in DKO cells (Supplementary
Figure S3). Bisulﬁte sequencing of this region
substantiated dense methylation in HCT116 and
DICER
ex5 cells and robust residual methylation at two
CpG sites in the DKO cells (Figure 1B). It is important
to note that DKO cells have lost >95% of its global DNA
methylation (24). Overall, we identiﬁed 59774 methylated
100-bp windows in DKO cells. Bisulﬁte sequencing of
seven such regions showed low but consistent levels of
residual methylation (Table 2). In this context, MBD
bound tightly to DNA fragments with residual
methylation rather than binding without speciﬁcity.
Consequently, we often observed in DKO cells a
disproportionally large number of reads for regions with
very low but robust DNA methylation. Nonetheless, loci
that are entirely lacking DNA methylation in DKO cells
still remain free of reads (Table 2). This indicates that
MiGS is highly speciﬁc and sensitive. Finally, we identiﬁed
diﬀerential methylation between HCT116 and DICER
ex5
cells at the intronic CpG island of ZEB1 (Fisher’s exact
test, two-tailed, P=3.1 10
 9) (Supplementary Figure
S4). Bisulﬁte sequencing corroborated this ﬁnding
(Figure 1C). VASH2 (P=5.1 10
 4) and PODXL2
(P=1.9 10
 6), also deemed to be diﬀerentially
methylated between HCT116 and DICER
ex5 cells, were
both conﬁrmed by bisulﬁte sequencing (Table 2).
We compared our results with previously reported
methylated gene promoters in HCT116 to estimate our
false negative rate (30) (Supplementary Table S2). We
deﬁned the proximal promoter as 500bp on either side
of the transcription start site. Our assay identiﬁed at
least one methylated 100-bp window within the proximal
PTCHD1
0 3 3 + 7 1 +
Peri 16
HCT116
DICERex5
DKO
5 0 4 , 9 6 8 , 3 3 7 4 0 , 9 6 8 , 3 3
ZEB1
1 9 0 2 + 5 9 6 1 +
C B A
Figure 1. Bisulﬁte sequencing of newly identiﬁed methylated regions. Bisulﬁte sequencing was performed on (A) peri-centromeric CpG island on
chromosome 16, (B) promoter CpG island of PTCHD1 and (C) ZEB1 intronic CpG island in HCT116, DICER
ex5 and DKO cells. Genomic
coordinates (NCBI Build 36.1) for the bisulﬁte sequencing amplicon of chromosome 16 peri-centromeric CpG island are shown. Positions relative to
the transcription start site are indicated for the amplicons of PTCHD1 and ZEB1. Each circle represents a CpG dinucleotide with black circles
representing methylated cytosines and white ones representing unmethylated cytosines. Each row represents one individual allele sequenced.
Rectangles above each cell line represent the non-overlapping 100-bp windows covered by each amplicon. Methylated windows identiﬁed by
MiGS are shaded in gray while unmethylated windows are in white.
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(87.5%). For two of the nine false negatives, EPHA4
and ZNF550, methylation signals were detected close to
our deﬁnition of the promoter. For EPHA4, methylation
was detected in the CpG island in the ﬁrst intron. ZNF550
showed methylation in a CpG island 4Kb upstream of the
transcription start site. We also analyzed by bisulﬁte
sequencing ﬁve randomly selected CpG islands without
evidence of DNA methylation in our datasets. All ﬁve
regions (GPAA1, SYPL1, NAPG, S/M and
NOTCH2NL) were found to be free of DNA methylation
(Table 2 and Supplementary Figure S5). Together, these
data indicate that MiGS can detect DNA methylated
regions on a genome-wide scale with very low false
positive and false negative rates.
Finally, we estimated whether the depth of sequencing
was suﬃcient to comprehensively characterize the entire
methylome. HCT116 and DICER
ex5 cells have similar
levels of global methylation, and we would expect their
methylation proﬁles to be similar. Indeed, 70.8% of all
signiﬁcantly methylated windows were detected in both
datasets. Additionally, windows with high number of
reads in HCT116 also displayed a high number of reads
in DICER
ex5 (Pearson’s r
2=0.84, P<2.2 10
 16).
Furthermore, we combined the present dataset (two
lanes of sequencing each for HCT116 and DICER
ex5)
with additional sequences generated from 3 and 2 lanes
of GAII from the same libraries. Using random sampling,
we assessed the number of methylated loci that can be
detected with diﬀerent number of sequencing reads. The
sampling curves showed that we did not reach saturation
in either sample and more methylated loci could be
identiﬁed with additional sequencing (Figure 2).
Nonetheless, >95% of highly methylated regions ( 10
reads) were captured with fewer than 8 million reads,
roughly the amount of data generated from a single
lane of GAII (Figure 2). Importantly, 56 out of 63
previously known methylated loci conﬁrmed by MiGS
(Supplementary Table S2) fell within this highly
methylated category. Thus, while additional sequences
might be necessary to identify all methylated loci, data
from two sequencing lanes are suﬃcient to exhaustively
characterize highly methylated loci.
MiGS describes distribution of DNA methylation in
the genome
MiGS data can also describe the distribution of DNA
methylation on a genome-wide scale. On average, 37%
of total sequencing reads from HCT116 and DICER
ex5
mapped to a unique location. Eighteen percent were
from repeat elements, mostly SINEs and rRNAs
(Supplementary Figure S1). An additional 22% mapped
only to the unassembled human genome and likely
represent centromeric/sub-telomeric regions (Table 1).
This pattern is consistent with previous ﬁndings that
DNA methylation prevents unwanted transcription and
maintains genome integrity by condensing these elements
(31). Globally, HCT116 and DICER
ex5 cells were virtually
identical in the distribution of DNA methylation, conﬁrm-
ing the previous report (23).
We further examined the genomic distribution of
unambiguously mapped DNA methylation (Table 3).
Promoter CpG island methylation has been the main
focus of most DNA methylation studies, but our data
indicate that the bulk of DNA methylation, 89% for
HCT116 and DICER
ex5 and 95% for DKO, occurs
outside of 50 promoter regions. Moreover, while a signif-
icant proportion of DNA methylation overlapped with
annotated CpG islands, >60% of DNA methylation
mapped outside of CpG islands. These observations
conﬁrm that DNA methylation has additional functions
in the genome other than facilitating transcriptional
silencing at proximal promoters. Such functions may
be achieved through methylation of non-CpG island
sequences as well as CpG islands.
Nonetheless, we observed preferential DNA
methylation within CpG islands in all genomic contexts.
CpG islands near transcription start sites are 4–7 times
more likely to be methylated than non-CpG islands in
the same context (Table 3). Interestingly, in all other
genomic contexts, CpG islands are 40–151 times more
likely to be methylated than non-CpG island sequences.
This observation is consistent with the notion that
promoter CpG islands are generally protected from
DNA methylation to allow transcription initiation.
MiGS identiﬁes biologically relevant DNA methylation
Since promoter DNA methylation is known to repress
gene transcription, we ﬁrst analyzed the distribution of
methylated regions with regards to RefSeq genes. To
assess whether DNA methylation at the 50-end of genes
has functional consequences, gene expression patterns
after removal of DNA methylation, by either 5-aza-20-
deoxycytidine (DAC) treatment or genetic deletion of
DNA methyltransferases in DKO cells, were examined
(Table 4). After demethylation, genes with methylation
at the 50-end showed a larger increase in expression
when compared with all other genes (Student’s t-test,
Figure 2. Sampling curves for HCT116 and DICER
ex5. The curves
show the number of 100-bp windows identiﬁed as being methylated
(y-axis) for a given number of sequences randomly drawn from the
entire dataset (x-axis). Blue lines represent sampling curves for
HCT116, and red lines correspond to data for DICER
ex5. The solid
lines show the results obtained when considering all signiﬁcantly
methylated windows ( 4 reads), while the dash lines represent the
results for highly methylated loci ( 10 reads) only. The vertical black
line shows the number of reads used in this study.
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 16). Interestingly, demethylation
of genes silenced by promoter CpG island
hypermethylation resulted in a higher increase of
transcripts when compared with demethylation of genes
with hypermethylated promoters that do not satisfy the
deﬁnition of a CpG island (P=0.0011 for DAC treatment
and P=0.0004 for DKO). Although promoter CpG
islands are protected from methylation, our data suggest
their hypermethylation leads to eﬃcient transcriptional
silencing. Promoters with methylated CpGs, but not
CpG islands, may be incompletely silenced. This hypoth-
esis would be consistent with the smaller changes in
expression observed when these genes are demethylated.
According to our data,  90% of the uniquely mapped
DNA methylation occurred outside of promoter regions
(Table 3). To begin understanding the biological role of
these marks, we compared them with CTCF binding sites
and microRNA (miRNA) coding sequences. CTCF
binding is blocked by DNA methylation (32), while
miRNA transcription can be silenced by DNA
methylation (33). Indeed, 16% of the detected DNA
methylation overlap with CTCF binding sites and 0.2%
overlap with miRNA coding regions (data not shown).
These percentages are likely underestimated since the
annotations for both CTCF binding sites and miRNA
coding regions are still incomplete. Nonetheless, they cor-
respond to a 4-fold enrichment of DNA methylation at
CTCF binding sites (Fisher’s exact test, two-tailed,
P<2.2 10
 16) and an 8-fold enrichment surrounding
miRNA coding sequences (P<2.2 10
 16). Although
CTCF binding and miRNA regulation cannot account
for all of the non-promoter DNA methylation we
detected, these comparisons indicate functional relevance
of non-promoter DNA methylation and underlie the
advantage of studying DNA methylation without
sequence context bias.
DISCUSSION
The functional genome is encoded and regulated by both
the nascent DNA sequences and epigenetic modiﬁcations,
such as DNA methylation. Therefore, in the post-genomic
era, there is a demand for genome-wide characterization
of epigenetic modiﬁcations to facilitate the full under-
standing of the utility and regulation of our genetic
material. However, the current methodologies of large-
scale DNA methylation proﬁling are insuﬃcient for
comprehensively surveying of DNA methylation in
multiple samples simultaneously. Bisulﬁte sequencing
requires the sequencing of the entire genome to map
DNA methylation patterns in each sample. Even with
massively parallel sequencing technologies, this is too
expensive for most laboratories and is impractical for
the study of multiple samples. Other types of assays rely
on the enrichment of methylated DNA sequences followed
Table 3. Distribution of DNA methylation
Hg18
a Distribution of methylation
b Methylation at CpG islands
c
HCT116 DICER
ex5 DKO HCT116 DICER
ex5 DKO
50-end 0.82% 11.29% 10.98% 4.83% 83.66% (7 ) 83.54% (7 ) 76.02% (4 )
30-end 0.71% 2.59% 2.56% 2.14% 51.14% (40 ) 50.82% (40 ) 43.06% (29 )
Genic 41.20% 50.20% 50.26% 60.92% 40.47% (98 ) 40.23% (97 ) 31.81% (67 )
Intergenic 57.26% 35.92% 36.20% 32.11% 36.51% (151 ) 35.88% (147 ) 23.49% (82 )
Total 100% 100% 100% 100% 44.20% (90 ) 43.67% (88 ) 31.52% (52 )
aProportion of the human genome (NCBI Build 36.1) located within 500bp of a RefSeq gene transcription start site (50-end), within 500bp of a
RefSeq gene transcription stop site (30-end), in the body of a RefSeq gene (Genic), or between RefSeq genes (Intergenic).
bDistribution of methylated 100-bp windows according to their genomic location.
cProportion of methylated windows that overlap with annotated CpG islands. The preferential enrichment of methylation at CpG islands is shown in
brackets and is calculated by dividing the proportion of methylated windows in CpG islands by the proportion of methylated windows not in CpG
islands in each genomic context.
Table 4. Gene expression changes of methylated genes upon demethylation
N Chemical demethylation Genetic demethylation
Mean change
a P-value Mean change
b P-value
50-end methylation 3031 1.57 <2.2 10
 16 1.81 2.2 10
 16
No methylation 16695 1.12 1.03
50-end CpG island methylation 2465 1.63 1.1 10
 3 1.91 3.6 10
 4
50-end non CpG island methylation 566 1.33 1.45
50-end non CpG island methylation 566 1.33 2.4 10
 3 1.45 4.4 10
 7
No methylation 16695 1.12 1.03
50end methylation 3031 1.57 <2.2 10
 16 1.81 <2.2 10
 16
Genic or 30-end methylation 5294 0.99 0.95
aAverage of ratios of gene expression in DAC-treated HCT116 cells over those in HCT116 cells.
bAverage of ratios of gene expression in DKO cells over those in HCT116 cells.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 397by detection of methylated regions by hybridizing the
DNA on tilling arrays (17,18). Such array-based
methods restrict the discovery of DNA methylation to
the probes present, which often focus on gene promoters,
CpG islands, and genic regions. Unsatisﬁed by these
current methods, we devised a technique combining pre-
cipitation of densely methylated genomic DNA by
recombinant MBD with massively parallel sequencing of
captured fragments to eﬃciently map DNA methylation
patterns in colon cancer cells.
We observed that an average of 38% of genomic DNA
methylation occurs in repeat elements and centromeric/
sub-telomeric regions. This is consistent with the notion
that DNA methylation is important for condensing these
genomic regions to provide structure and protect against
unwanted transcription. Furthermore, a large fraction of
uniquely mapped DNA methylation resides outside of
gene promoters (>88%) and CpG islands (>55%).
These would likely be missed by most custom arrays,
which typically focus on CpG islands and/or gene
promoters. The inclusion of DNA methylation data in
all genomic contexts is another advantage of MiGS over
existing technologies.
Furthermore, by comparing these genome-wide DNA
methylation patterns to gene expressions, CTCF binding
sites, and miRNA coding regions, we were able to assign
functional roles for the detected DNA methylation. We
observed that gene promoter methylation robustly
correlates with transcriptional silencing, regardless of
whether the sequence qualiﬁes as a CpG island. We also
found that non-promoter DNA methylation overlaps with
CTCF binding sites and miRNA coding regions and there-
fore, is likely to be biologically relevant. These informa-
tion would, again, be missed by many array-based
detection methods.
With only two lanes of sequencing per sample,
we detected both known DNA methylation and
identiﬁed numerous novel methylated regions in these
cells with low false positive and false negative rates.
Although additional sequencing could identify more
methylated loci, >95% of the highly methylated loci,
which include the majority of genes previously
described, can be captured with merely two lanes of
GAII sequencing. By comparison, more than 100 lanes
of sequencing on the same instrument are required
to obtain the same information using bisulﬁte
sequencing. One disadvantage of MiGS, as compared
to bisulﬁte sequencing, is that the description of
methylation is not at single base pair resolution; rather,
the resolution depends on the fragment size of the
sonicated DNA. Thus, fragments determined to be
methylated by MiGS can contain individual CpG sites
that are not methylated. However, MiGS can focus
bisulﬁte sequencing eﬀorts to fragments that are
signiﬁcantly methylated. By doing so, the cost of
analyzing methylation on a genome-wide scale, even at
single base pair resolution, is substantially reduced.
Our data support that MiGS is a sensitive, speciﬁc,
thorough, and cost-eﬀective method for studying
genome-wide DNA methylation.
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